An aggressive immature hematologic neoplasm formerly known as blastic NK cell lymphoma, composed of cells with a lymphoblast-like morphology. Recent evidence suggests derivation from a plasmacytoid mo...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation regarding CD4+/CD56+ hematodermic neoplasm is limited primarily due to its rarity, affecting fewer than 5 in 10,000 individuals. This low prevalence restricts the ability to conduct large-scale clinical studies, resulting in gaps in knowledge about its genetic basis and clinical features. Additionally, the condition's recent recognition as a distinct entity has led to ongoing efforts to better characterize its clinical presentation and treatment options.
To navigate your care for CD4+/CD56+ hematodermic neoplasm, it's essential to seek a hematologist or an oncologist with expertise in rare hematologic malignancies. They can guide you through treatment options and clinical trials. You may also consider participating in clinical trials, which can provide access to cutting-edge therapies. For additional resources, visit the National Organization for Rare Disorders (NORD) at https://rarediseases.org. While there are no specific patient organizations for this condition, connecting with broader cancer support groups may offer valuable assistance.
There are currently 21 active clinical trials investigating CD4+/CD56+ hematodermic neoplasm. One FDA-approved treatment is Tagraxofusp-erzs, while additional orphan drugs in development include autologous T cells genetically modified to express CD123-specific chimeric receptors. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=CD4%2B%2FCD56%2B%20hematodermic%20neoplasm. This research landscape offers hope for improved treatment options in the future.
Actionable guidance for navigating care for CD4+/CD56+ hematodermic neoplasm
To navigate your care for CD4+/CD56+ hematodermic neoplasm, it's essential to seek a hematologist or an oncologist with expertise in rare hematologic malignancies. They can guide you through treatment options and clinical trials. You may also consider participating in clinical trials, which can provide access to cutting-edge therapies. For additional resources, visit the National Organization for Rare Disorders (NORD) at https://rarediseases.org. While there are no specific patient organizations for this condition, connecting with broader cancer support groups may offer valuable assistance.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation regarding CD4+/CD56+ hematodermic neoplasm is limited primarily due to its rarity, affecting fewer than 5 in 10,000 individuals. This low prevalence restricts the ability to conduct large-scale clinical studies, resulting in gaps in knowledge about its genetic basis and clinical features. Additionally, the condition's recent recognition as a distinct entity has led to ongoing efforts to better characterize its clinical presentation and treatment options.
To navigate your care for CD4+/CD56+ hematodermic neoplasm, it's essential to seek a hematologist or an oncologist with expertise in rare hematologic malignancies. They can guide you through treatment options and clinical trials. You may also consider participating in clinical trials, which can provide access to cutting-edge therapies. For additional resources, visit the National Organization for Rare Disorders (NORD) at https://rarediseases.org. While there are no specific patient organizations for this condition, connecting with broader cancer support groups may offer valuable assistance.
There are currently 21 active clinical trials investigating CD4+/CD56+ hematodermic neoplasm. One FDA-approved treatment is Tagraxofusp-erzs, while additional orphan drugs in development include autologous T cells genetically modified to express CD123-specific chimeric receptors. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=CD4%2B%2FCD56%2B%20hematodermic%20neoplasm. This research landscape offers hope for improved treatment options in the future.
Actionable guidance for navigating care for CD4+/CD56+ hematodermic neoplasm
To navigate your care for CD4+/CD56+ hematodermic neoplasm, it's essential to seek a hematologist or an oncologist with expertise in rare hematologic malignancies. They can guide you through treatment options and clinical trials. You may also consider participating in clinical trials, which can provide access to cutting-edge therapies. For additional resources, visit the National Organization for Rare Disorders (NORD) at https://rarediseases.org. While there are no specific patient organizations for this condition, connecting with broader cancer support groups may offer valuable assistance.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation regarding CD4+/CD56+ hematodermic neoplasm is limited primarily due to its rarity, affecting fewer than 5 in 10,000 individuals. This low prevalence restricts the ability to conduct large-scale clinical studies, resulting in gaps in knowledge about its genetic basis and clinical features. Additionally, the condition's recent recognition as a distinct entity has led to ongoing efforts to better characterize its clinical presentation and treatment options.
To navigate your care for CD4+/CD56+ hematodermic neoplasm, it's essential to seek a hematologist or an oncologist with expertise in rare hematologic malignancies. They can guide you through treatment options and clinical trials. You may also consider participating in clinical trials, which can provide access to cutting-edge therapies. For additional resources, visit the National Organization for Rare Disorders (NORD) at https://rarediseases.org. While there are no specific patient organizations for this condition, connecting with broader cancer support groups may offer valuable assistance.
There are currently 21 active clinical trials investigating CD4+/CD56+ hematodermic neoplasm. One FDA-approved treatment is Tagraxofusp-erzs, while additional orphan drugs in development include autologous T cells genetically modified to express CD123-specific chimeric receptors. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=CD4%2B%2FCD56%2B%20hematodermic%20neoplasm. This research landscape offers hope for improved treatment options in the future.
Actionable guidance for navigating care for CD4+/CD56+ hematodermic neoplasm
To navigate your care for CD4+/CD56+ hematodermic neoplasm, it's essential to seek a hematologist or an oncologist with expertise in rare hematologic malignancies. They can guide you through treatment options and clinical trials. You may also consider participating in clinical trials, which can provide access to cutting-edge therapies. For additional resources, visit the National Organization for Rare Disorders (NORD) at https://rarediseases.org. While there are no specific patient organizations for this condition, connecting with broader cancer support groups may offer valuable assistance.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.